New cancer diagnoses are expected to rise by 70% in the next two decades. Early detection of cancer greatly reduces survival rates. Current standards of care are either highly invasive/highly accurate or non-invasive/not accurate. Blood-based cancer diagnostics are non-invasive, repeatable, and increasingly accurate. As such, they represent a very big venture capital opportunity.